Head-to-head · WeighScore
AM Rx vs Fierce Health
The verdict
Fierce Health takes it — 56.6/100 to 49.9/100.
Fierce Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fierce Health is a direct-to-consumer telehealth brand selling compounded semaglutide and tirzepatide in both standard and microdose programs, alongside a longevity catalog.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AM Rx | Fierce Health |
|---|---|---|
| WeighScore | 49.9/100 | 56.6/100 |
| Grade | C | C |
| Scorecard rank | #490 | #410 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | $297/mo (3-month plan, compounded) |
| Tirzepatide | Not disclosed | $497/mo (3-month plan, compounded) |
| Coverage | Coverage not published | 30 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #490 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #410 · C
Strengths
- 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer on every product page
- Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
- Microdose tier at $197/mo is one of the lower entry points we've seen
Where it loses points
- No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
- Operating LLC name not disclosed anywhere on the site
- Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
- Clinical provider network not named
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.